What are Stock Advisors saying about Infinity Pharmaceuticals, Inc. (INFI)

Josh Kim
January 28, 2017

The stock was sold at an average price of $1.30, for a total transaction of $32,511.70.

Several other equities research analysts have also recently commented on the stock. Strong Sell rating was given by 1 brokerage firms. J P Morgan Chase & Co reiterated a "buy" rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, January 11th. The analyst recommendations from a month ago are 4 Buy, 0 Overweight, 0 Sell, 1 Hold and 0 Underweight.

The latest Upgrades/Downgrades was done by Research firm Wells Fargo on 15-Jun-16 who Downgrade the stock from Outperform to Market Perform. Even as the interest increased from 1,641,916 shares on December 30,2016 to 1,888,027 shares on January 13,2017, the days to cover came in at 4. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The company has a market cap of $3.82B and now has 122.71M shares outstanding. The stock is now moving above its 20-Day Simple Moving Average of 8.25% with the 50-Day Simple Moving Average of 8.25 percent.

Infinity Pharmaceuticals (NASDAQ:INFI) traded up 4.50% during trading on Monday, hitting $2.09. Current price places the company's stock -9.14% away from its 200-day simple moving average, 53.81%, away from the 50-day average and also 37.69% away from 20-day average. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.86) by $0.47. The company gross profit margin is 58.60%. The company's revenue was up 13489.7% compared to the same quarter a year ago. Equities research analysts predict that ACADIA Pharmaceuticals will post ($2.35) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of worldwide trademark & copyright law. The stock has a 50 day moving average price of $29.08 and a 200-day moving average price of $30.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The company will report its next earnings on Feb 21 - Feb 27 (Est.).

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 10,000 shares of the business's stock in a transaction dated Tuesday, December 20th. Prudential Financial Inc. now owns 8,458 shares of the biopharmaceutical company's stock worth $269,000 after buying an additional 400 shares during the last quarter. Principal Financial Group Inc. increased its stake in ACADIA Pharmaceuticals by 28.1% in the second quarter. MD now owns 283,960 shares of the company's stock valued at $443,000 after buying an additional 173,360 shares during the last quarter. The number of shares now owned by investors are 122.38 mln. Numeric Investors LLC raised its stake in Infinity Pharmaceuticals by 699.4% in the second quarter. The original version of this article can be accessed at https://www.com-unik.info/2017/01/26/acadia-pharmaceuticals-inc-acad-rating-reiterated-by-needham-company-llc.html. It has a past 5-day performance of 23.84 percent and trades at an average volume of 851.75K shares. Baker BROS. Advisors LP purchased a new stake in Infinity Pharmaceuticals during the third quarter valued at $905,000. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company develops small molecule drugs that target disease pathways for potential applications in oncology.

Other reports by MyHealthBowl

Discuss This Article

FOLLOW OUR NEWSPAPER